research Alopecia areata treatment with baricitinib: different relapse phenotypes
Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
Search
for
Did you mean Relapse?
Research
5 / 1000+ resultsresearch Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.
research Relapse of hirsutism following long‐term successful treatment with oestrogen–progestogen combination
This study found that while ethinyl oestradiol and cyproterone acetate effectively treated hirsutism in 90% of patients, 80% experienced relapse within six months after stopping treatment, suggesting long-term use is necessary.
research Relapse of Alopecia Areata Responders After Tofacitinib Withdrawal: A Retrospective Study of 59 Patients
Many patients with alopecia areata relapse after stopping tofacitinib.
research Clinical Profile and Predictors of Relapse in Patients with Alopecia Areata: A Follow-Up Study
This study found that a high proportion of alopecia areata patients experienced a relapse, typically within one year, with more extensive initial scalp involvement predicting an earlier return of the disease.
Community Join
2 / 1000+ resultscommunity 1 Year Timeline (Fin/Dut, Min) + Some Questions
A user shared their one-year hair loss treatment journey using finasteride, dutasteride, and minoxidil, noting initial success with minoxidil but experiencing relapses. They questioned the effectiveness of dutasteride compared to finasteride and expressed frustration with the non-linear progress and the inconvenience of using both oral and topical treatments.
community Spironolactone and pregnancy planning
A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.
Learn
— no results
Experts
— no results
Clinics
— no results